Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093895 | 0.87 | ATR (0.36) | NR3C1RORCDGAT2ATRIDO1 | |
| SCHEMBL31093709 | 0.84 | NR3C1 (0.33) | NR3C1RORCDGAT2BRD4ATR | |
| SCHEMBL30861007 | 0.84 | BRD9 (0.37) | NR3C1RORCDGAT2BRD4ATR | |
| SCHEMBL31093693 | 0.79 | ATR (0.35) | NR3C1RORCATR | |
| SCHEMBL31093770 | 0.77 | ATR (0.35) | ATR | |
| SCHEMBL31093786 | 0.73 | CYP4F2 (0.37) | RORCATR | |
| SCHEMBL27227929 | 0.72 | RXRA (0.38) | NR3C1DGAT2 | |
| SCHEMBL31093852 | 0.70 | ATR (0.35) | ATR | |
| SCHEMBL31093850 | 0.70 | ATR (0.34) | RORCATR | |
| SCHEMBL31093715 | 0.68 | KIT (0.41) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024179948-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | NR3C1 1638/4885RORC 2507/4885DGAT2 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.